A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration
Clinical trial NCT05639530 · COMPLETED
Trial details
- NCT number
- NCT05639530
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-27
- Primary completion
- 2023-12-07
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.